AV078
Phase 2Small molecule
AV078 is one of 8 small molecule programs targeting Tuberous Sclerosis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Tuberous Sclerosis
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Epidiolex
Jazz PharmaceuticalsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Fintepla
IImmedica Pharma AB
Approved
Sabril
LundbeckPhase 3
Rapamycin
MMaastricht Radiation Oncology
Phase 3
AV078
AAeovian Pharmaceuticals, Inc.
Phase 2
Epidiolex /ml
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AV078. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAeovian Pharmaceuticals, Inc.